Factors predicting the response to oral fluoropyrimidine drugs: A phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study)

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 437-444

  Mori, Takeo ^a   Ohue, Masayuki ^b   Takii, Yasumasa ^c   Hashizume, Tadashi ^d   Kato, Tomoyuki ^e   Kotake, Kenjiro ^f   Sato, Toshihiko ^g   Tango, Toshiro ^h  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d Mutsu General Hospital   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TOCHIGI CANCER CENTER   (Japan)

^g Yamagata Prefectural Central Hospital   (Japan)

^h Center for Medical Statistics   (Japan)

Author keywords

Biomarkers; Disease free survival; Predictive markers; Thymidine phosphorylase dihydropyrimidine dehydrogenase ratio

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UFT;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER STAGING; COLORECTAL CANCER; COLORECTAL SURGERY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INDIVIDUALIZATION; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN PIGMENTATION; STOMACH PAIN; STOMATITIS; TANDEM REPEAT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872769167     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2177     Document Type: Article

References (33)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan: http://ganjoho.ncc.go.jp/public/statistics/index.html. Accessed August 16, 2011.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: 939-944, 1995.
3. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23: 8671-8678, 2005. (Pubitemid 46211510)
4. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 355: 1588-1596, 2000.
5. André T, Quinaux E, Louvet C, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25: 3732-3738, 2007. (Pubitemid 47372615)
6. Twelves C, Wong A, Nowacki M P, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704, 2005. (Pubitemid 41007824)
7. Lembersky BC, Wieand HS, Petrelli NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064, 2006. (Pubitemid 46622115)
8. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxyfluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998. (Pubitemid 28099478)
9. Nishimura G, Terada I, Kobayashi T, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9: 479-482, 2002.
10. Ichikawa W, Uetake H, Shirota Y, et al: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003. (Pubitemid 37386604)
11. Sakamoto J, Ohashi Y, Hamada C, et al: Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22: 484-492, 2004. (Pubitemid 41079778)
12. Nishida M, Hino A, Mori K, et al: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996. (Pubitemid 26403242)
13. Mori K, Hasegawa M, Nishida M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
14. Kawakami K and Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004-6007, 2003. (Pubitemid 37187503)
15. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998. (Pubitemid 28183404)
16. Gieschke R, Burger HU, Reigner B, et al: Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55: 252-263, 2003. (Pubitemid 36390755)
17. Patterson AV, Zhang H, Moghaddam A, et al: Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675, 1995.
18. Evrard A, Cuq P, Ciccolini J, et al: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80: 1726-1733, 1999. (Pubitemid 29389624)
19. Toi M, Rahman MA, Bando H and Chow LW: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 158-166, 2005. (Pubitemid 40309127)
20. Eda H, Fujimoto K, Watanabe S, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993. (Pubitemid 23207988)
21. Miyadera K, Sumizawa T, Haraguchi M, et al: Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55: 1687-1690, 1995.
22. Lenz HJ, Hayashi K, Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998. (Pubitemid 28213336)
23. Paradiso A, Simone G, Petroni S, et al: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560-567, 2000. (Pubitemid 30085191)
24. Sinicrope FA, Rego RL, Halling KC, et al: Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 12: 2738-2744, 2006.
25. Ochiai T, Nishimura K, Noguchi H, et al: Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118: 3084-3088, 2006.
26. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
27. Lassmann S, Hennig M, Rosenberg R, et al: Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors- correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 21: 238-247, 2006. (Pubitemid 43280331)
28. Ciaparrone M, Quirino M, Schinzari G, et al: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70: 366-377, 2006. (Pubitemid 46066130)
29. Park DJ, Stoehlmacher J, Zhang W, et al: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17: 46-49, 2002. (Pubitemid 41398991)
30. Park CM, Lee WY, Chun HK, et al: Relationship of polymor phism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. J Surg Oncol 101: 22-27, 2010.
31. Goto H, Kohno K, Sone S, et al: Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res 61: 469-473, 2001. (Pubitemid 32128599)
32. Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996. (Pubitemid 26274605)
33. Tokunaga Y, Hosogi H, Hoppou T, et al: Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery 131: 541-547, 2002. (Pubitemid 34478503)